Welcome to our dedicated page for Recursion Pharmaceuticals news (Ticker: RXRX), a resource for investors and traders seeking the latest updates and insights on Recursion Pharmaceuticals stock.
Recursion Pharmaceuticals, Inc. develops investigational medicines as a clinical-stage TechBio company using the Recursion OS, an AI-native drug discovery and development platform that integrates biology, chemistry, automation, data science and clinical development. Company updates center on wholly owned and partnered programs in oncology, rare disease, neuroscience, immunology and other therapeutic areas.
Recurring announcements cover clinical and preclinical pipeline progress, financial results, platform infrastructure, automated laboratory operations, collaborations and partner milestones. Recursion also reports governance and leadership changes, investor-conference participation and updates tied to named programs such as REC-1245, REC-4881 and REC-4539 when those programs advance through development.
Recursion (Nasdaq: RXRX) named Vicki Goodman, M.D. as Chief Medical Officer effective April 6, 2026, succeeding David Mauro, M.D., Ph.D., who will transition from the role after approximately three years.
Recursion highlighted Dr. Goodman’s late‑stage oncology and regulatory experience as supportive for advancing its clinical pipeline, including ongoing progression of REC‑4881.
Recursion (NASDAQ: RXRX) reported fourth-quarter and full-year 2025 results and a business update highlighting clinical validation of its AI Operating System, material partnered milestone receipts, and a strong cash position. Key points: REC-4881 showed meaningful polyp reductions in FAP, the company holds $754 million in cash, and management expects runway into early 2028.
Recursion achieved a fifth Sanofi milestone, advanced multiple discovery programs, reported revenue growth in 2025, and delivered operating efficiencies with 2025 cash operating expense near $399 million.
Recursion (Nasdaq: RXRX) will be featured in HighRes’ Lightning Talk at NVIDIA GTC March 16–19, 2026 in San Jose. The session highlights AI agents, robotics, and digital twins supporting self-driving, high-throughput labs and biomanufacturing.
Presenters include HighRes CEO Ira Hoffman, NVIDIA moderator Stacie Calad-Thomson, and representatives from Multiply Labs and Thermo Fisher. Recursion says it operates integrated wet and dry labs, generates millions of multi-omic data points weekly, and leverages its NVIDIA-backed supercomputer BioHive-2 to train ML models for drug discovery.
Recursion (Nasdaq: RXRX) will participate in multiple investor conferences in March 2026, presenting company updates and management outlooks.
Scheduled events include TD Cowen (March 2), Leerink Partners (March 9), Jefferies Biotech on the Beach (March 11), and KeyBanc Healthcare Forum (March 17). Webcasts are available in the events section at the company investor relations site.
Recursion (Nasdaq: RXRX) will report fourth quarter and full year 2025 business updates and financial results on Wednesday, February 25, 2026, before market open. The company will host a public (L)earnings call at 8:00 AM ET / 6:00 AM MT / 1:00 PM GMT.
The live stream will be broadcast on Recursion’s X, LinkedIn, and YouTube accounts, and investors may submit questions in advance via the company’s online form.
Recursion (NASDAQ: RXRX) announced that on February 6, 2026 its Compensation Committee approved inducement restricted stock unit awards covering 820,431 shares of Class A common stock granted to 17 new employees under the 2024 Inducement Equity Incentive Plan.
Each RSU vests 25% at the first quarterly vesting date on or after the one-year anniversary of the vesting commencement date, then vests at 1/16th each quarter thereafter, subject to continued employment and plan/grant agreement terms. Grants were made pursuant to Nasdaq Listing Rule 5635(c)(4).
Recursion (Nasdaq: RXRX) announced that CEO & President Najat Khan, Ph.D. will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026 at 10:30am PT in San Francisco.
Management will also participate in the 28th Annual Needham Growth Conference on Friday, January 16, 2026. Webcasts will be available in the events section of Recursion Investor Relations at ir.recursion.com.
Recursion (NASDAQ: RXRX) reported positive Phase 1b/2 TUPELO results for REC-4881 in familial adenomatous polyposis (FAP) on Dec 8, 2025. REC-4881 (4 mg QD) produced a 43% median polyp-burden reduction at 12 weeks (n=12) with 75% of evaluable patients showing reductions. At Week 25—12 weeks after stopping therapy—82% (9 of 11) maintained reductions with a 53% median decrease from baseline. Safety was consistent with MEK1/2 inhibition: mostly Grade 1–2 TRAEs, 15.8% Grade 3, and no Grade ≥4 reported. Natural-history data showed 87% of similar untreated FAP patients had annualized polyp increases (n=55). Next steps include FDA engagement in 1H26 and population/dosing expansion.
Recursion (Nasdaq: RXRX) will host a webinar on December 8, 2025 to present an updated clinical readout from the ongoing TUPELO Phase 1b/2 trial of REC-4881 in familial adenomatous polyposis (FAP).
The live webinar is scheduled for 8:00 AM ET / 6:00 AM MT / 1:00 PM GMT and will stream on Recursion's X, LinkedIn, and YouTube channels. The session is titled: Ongoing Phase 1b/2 Trial of the Allosteric MEK1/2 Inhibitor REC-4881 as Monotherapy in Familial Adenomatous Polyposis (FAP): Updated Safety and Efficacy.
Presenters include Najat Khan, Ph.D. (incoming CEO and President), David Mauro, M.D., Ph.D., Beth Bruckheimer, Ph.D., Jessica Stout, D.O., and Alfred Cohen, M.D.
Recursion (Nasdaq: RXRX) reported Q3 2025 results and a business update on Nov 5, 2025, highlighting a $30 million milestone from Roche/Genentech for a microglia whole-genome phenomap and surpassing $500 million in cumulative partner upfronts and milestones. Cash and cash equivalents were $667.1M as of Sept 30, 2025 and approximately $785M as of Oct 9, 2025 (unaudited), with an expected runway through end of 2027 absent additional financing. Q3 revenue was $5.2M vs $26.1M year-ago; R&D expenses were $121.1M; net loss was $162.3M. Pipeline progress included REC-617 dose escalation, REC-7735 nominated as a development candidate, and REC-4881 data due Dec 2025.